QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NASDAQ:SRZN

Surrozen (SRZN) Stock Price, News & Analysis

$12.78
-0.92 (-6.72%)
(As of 02/22/2024 ET)
Today's Range
$12.00
$13.25
50-Day Range
$7.60
$13.99
52-Week Range
$4.50
$18.00
Volume
11,209 shs
Average Volume
16,000 shs
Market Capitalization
$26.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SRZN stock logo

About Surrozen Stock (NASDAQ:SRZN)

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.

SRZN Stock Price History

SRZN Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Surrozen Provides Corporate Update on Clinical Programs
3 Biotech Stocks to Watch in November
The perfect AI stock under $10
Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. This #1 AI company is at the forefront of it all.
Surrozen Provides Third Quarter 2023 Financial Results
Surrozen Inc Ordinary Shares SRZN
Surrozen GAAP EPS of -$0.31
Surrozen: Q1 Earnings Insights
Surrozen's Earnings: A Preview
See More Headlines
Receive SRZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
2/22/2024
Next Earnings (Estimated)
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:SRZN
Fax
N/A
Employees
74
Year Founded
N/A

Profitability

Net Income
$-36,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$12.50 million
Book Value
$37.87 per share

Miscellaneous

Free Float
1,325,000
Market Cap
$26.07 million
Optionable
Not Optionable
Beta
0.39
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Craig C. Parker M.B.A. (Age 62)
    CEO, President & Director
    Comp: $753.3k
  • Mr. Charles Williams (Age 43)
    CFO, COO & Corporate Secretary
    Comp: $563.49k
  • Dr. K. Christopher Garcia Ph.D.
    Co-Founder & Member of Scientific Advisor
  • Dr. Roeland Nusse Ph.D. (Age 74)
    Co-Founder & Member of Scientific Advisor
  • Dr. Calvin Kuo M.D.
    Ph.D., Co-Founder & Member of Scientific Advisor
  • Dr. Li Yang Ph.D.
    Executive Vice President of Research
  • Esther Jhun
    Controller














SRZN Stock Analysis - Frequently Asked Questions

How have SRZN shares performed in 2024?

Surrozen's stock was trading at $9.40 at the beginning of 2024. Since then, SRZN stock has increased by 36.0% and is now trading at $12.78.
View the best growth stocks for 2024 here
.

Are investors shorting Surrozen?

Surrozen saw a decline in short interest in the month of January. As of January 31st, there was short interest totaling 5,600 shares, a decline of 46.2% from the January 15th total of 10,400 shares. Based on an average trading volume of 11,900 shares, the short-interest ratio is presently 0.5 days. Approximately 0.3% of the shares of the company are sold short.
View Surrozen's Short Interest
.

When is Surrozen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our SRZN earnings forecast
.

How were Surrozen's earnings last quarter?

Surrozen, Inc. (NASDAQ:SRZN) issued its quarterly earnings results on Monday, November, 15th. The company reported ($7.65) earnings per share for the quarter, missing analysts' consensus estimates of ($5.85) by $1.80.

When did Surrozen's stock split?

Surrozen shares reverse split on the morning of Thursday, December 14th 2023. The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Surrozen's major shareholders?

Surrozen's stock is owned by a number of retail and institutional investors. Top institutional investors include Column Group LLC (30.77%), Board of Trustees of The Leland Stanford Junior University (2.56%) and Vanguard Group Inc. (1.59%).

How do I buy shares of Surrozen?

Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRZN) was last updated on 2/22/2024 by MarketBeat.com Staff